The US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to a novel treatment of Gram-negative bacterial infections. CTX-187, developed by immunotherapy company Centauri Therapeutics, is a novel immunotherapeutic approach to treat Gram-negative bacterial infections. It is hoped the therapeutic, currently in preclinical… Read More
Immunotherapy company Centauri Therapeutics has extended its Series A financing to £30 million ($40.6 million) to support its lead candidate targeting Gram-negative bacterial infections. The funding was extended thanks to a £6m ($8.1 million) investment from the AMR Action Fund. The financing from AMR Action Fund, the world’s… Read More
GSK and the Fleming Initiative have launched six major new research programmes aiming to combat antimicrobial resistance (AMR). The six ‘Grand Challenges’ will bring together scientific expertise and the latest technologies, including AI, to find new ways to slow the progress of AMR. The project has been backed by… Read More
A new paper has presented the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections. The study in The Journal of Immunology presents proof-of-concept data for CTX-09, an early molecule built on Centauri Therapeutics’ Alphamer platform. In… Read More
Infex Therapeutics, in collaboration with Justus-Liebig-University Giessen (JLU), Germany, has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy). The company plans to develop a first-in-class BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens. BamA inhibitors are an entirely new class of… Read More
Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the gut. The drug, called lolamicin, also warded off secondary infections with Clostridioides difficile, and was effective against more than… Read More
A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint. The RACERS study included 20 patients with gram-negative sepsis who were at high risk for acute kidney… Read More
An international team of researchers has discovered a new antibiotic by computational analysis and deciphered its mode of action. The researchers also found that Dynobactin kills Gram-negative bacteria, which include many dangerous and resistant pathogens. The team were led by researchers from the Northeastern University… Read More
